Bone status in juvenile systemic lupus erythematosus

Lupus

Volumn 16, Issue 8, 2007, Pages 580-586

  Lilleby, Vibke ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; GLUCOCORTICOID; VITAMIN D;

ADOLESCENT; BONE MASS; BONE METABOLISM; CONTROLLED STUDY; DRUG DOSE REDUCTION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

ABSORPTIOMETRY, PHOTON; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; CHILD; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; REPRODUCIBILITY OF RESULTS;

EID: 34548400388     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307079040     Document Type: Review

References (61)

1. Ramsey-Goldman R, Dunn JE, Huang CF et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 1999; 42: 882-890.
2. Formiga F, Moga I, Nolla JM, Pac M, Mitjavila F, Roig-Escofet D. Loss of bone mineral density in premenopausal women with systemic lupus erythematosus. Ann Rheum Dis 1995; 54: 274-276.
3. Gilboe IM, Kvien TK, Haugeberg G, Husby G. Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls. Ann Rheum Dis 2000; 59: 110-115.
4. Houssiau FA, Lefebvre C, Depresseux G, Lambert M, Devogelaer JP, Nagant dD. Trabecular and cortical bone loss in systemic lupus erythematosus. Br J Rheumatol 1996; 35: 244-247.
5. Kipen Y, Briganti E, Strauss B, Will R, Littlejohn G, Morand E. Three year followup of bone mineral density change in premenopausal women with systemic lupus erythematosus. J Rheumatol 1999; 26: 310-317.
6. Pons F, Peris P, Guanabens N et al. The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in pre-menopausal women. Br J Rheumatol 1995; 34: 742-746.
7. Sinigaglia L, Varenna M, Binelli L et al. Determinants of bone mass in systemic lupus erythematosus: a cross sectional study on premenopausal women. J Rheumatol 1999; 26: 1280-1284.
8. Teichmann J, Lange U, Stracke H, Federlin K, Bretzel RG. Bone metabolism and bone mineral density of systemic lupus erythematosus at the time of diagnosis. Rheumatol Int 1999; 18: 137-140.
9. Bachrach LK. Dual energy X-ray absorptiometry (DEXA) measurements of bone density and body composition: promise and pitfalls, J Pediatr Endocrinol Metab 2000; 13(Suppl 2): 983-988.
10. Bachrach LK. Acquisition of optimal bone mass in childhood and adolescence. Trends Endocrinol Metab 2001; 12: 22-28.
11. Cassidy JT. Osteopenia and osteoporosis in children. Clin Exp Rheumatol 1999; 17: 245-250.
12. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137-1141.
13. Alsufyani KA, Ortiz-Alvarez O, Cabral DA et al. Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. J Rheumatol 2005; 32: 729-733.
14. Lien G, Flato B, Haugen M et al. Frequency of osteopenia in adolescents with early-onset juvenile idiopathic arthritis: a long-term outcome study of one hundred five patients. Arthritis Rheum 2003; 48: 2214-2223.
15. Lilleby V, Lien G, Frey Frøslie K, Haugen M, Flatø B, Førre Ø. Frequency of osteopenia in children and young adults with childhood-onset systemic lupus erythematosus. Arthritis Rheum 2005; 52: 2051-2059.
16. Rabinovich CE. Osteoporosis: a pediatric perspective. Arthritis Rheum 2004; 50: 1023-1025.
17. Miller PD, Hochberg MC, Wehren LE, Ross PD, Wasnich RD. How useful are measures of BMD and bone turnover? Curr Med Res Opin 2005; 21: 545-554.
18. Foster BJ, Leonard MB. Measuring nutritional status in children with chronic kidney disease. Am J Clin Nutr 2004; 80: 801-814.
19. Pietrobelli A, Formica C, Wang Z, Heymsfield SB. Dual-energy X-ray absortiometry body composition model: review of physical concepts. Am J Physiol 1996; 271: E941-E951.
20. Mazess RB, Barden HS, Bisek JP, Hanson J. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr 1990; 51: 1106-1112.
21. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 1996; 312: 1254-1259.
22. Friedman AW. Important determinants of bone strength: beyond bone mineral density. J Clin Rheumatol 2006; 12: 70-77.
23. Carter DR, Bouxsein ML, Marcus R. New approaches for interpreting projected bone densitometry data. J Bone Miner Res 1992; 7: 137-145.
24. Gafni RI, Baron J. Overdiagnosis of osteoporosis in children due to misinterpretation of dual-energy x-ray absorptiometry (DEXA). J Pediatr 2004; 144: 253-257.
25. Leonard MB. Assessment of bone health in children and adolescents with cancer: promises and pitfalls of current techniques. Med Pediatr Oncol 2003; 41: 198-207.
26. Prentice A, Parsons TJ, Cole TJ. Uncritical use of bone mineral density in absorptiometry may lead to size-related artifacts in the identification of bone mineral determinants. Am J Clin Nutr 1994; 60: 837-842.
27. Falcini F, Bindi G, Simonini G et al. Bone status evaluation with calcaneal ultrasound in children with chronic rheumatic diseases. A one year followup study. J Rheumatol 2003; 30: 179-184.
28. Castro TC, Terreri MT, Szejnfeld VL et al. Bone mineral density in juvenile systemic lupus erythematosus. Braz J Med Biol Res 2002; 35: 1159-1163.
29. Trapani S, Civinini R, Ermini M, Paci E, Falcini F. Osteoporosis in juvenile systemic lupus erythematosus: a longitudinal study on the effect of steroids on bone mineral density. Rheumatol Int 1998; 18: 45-49.
30. Szulc P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 2000; 11: 281-294.
31. Segal LG, Lane NE. Osteoporosis and systemic lupus erythematosus: etiology and treatment strategies. Ann Med Interne (Paris) 1996; 147: 281-289.
32. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000; 15: 2-12.
33. Lee C, Ramsey-Goldman R. Osteoporosis in systemic lupus erythematosus mechanisms. Rheum Dis Clin North Am 2005; 31: 363-385, viii.
34. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332: 305-311.
35. Tanaka Y, Watanabe K, Suzuki M et al. Spontaneous production of bone-resorbing lymphokines by B cells in patients with systemic lupus erythematosus. J Clin Immunol 1989; 9: 415-420.
36. Canalis E, Giustina A. Glucocorticoid-induced osteoporosis: summary of a workshop. J Clin Endocrinol Metab 2001; 86: 5681-5685.
37. Sambrook PN. Corticosteroid osteoporosis: practical implications of recent trials. J Bone Miner Res 2000; 15: 1645-1649.
38. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998; 102: 274-282.
39. Bhattoa HP, Kiss E, Bettembuk P, Balogh A. Bone mineral density, biochemical markers of bone turnover, and hormonal status in men with systemic lupus erythematosus. Rheumatol Int 2001; 21: 97-102.
40. Formiga F, Nolla JM, Mitjavila F, Bonnin R, Navarro MA, Moga I. Bone mineral density and hormonal status in men with systemic lupus erythematosus. Lupus 1996; 5: 623-626.
41. Prentice A. Diet, nutrition and the prevention of osteoporosis. Public Health Nutr 2004; 7: 227-243.
42. American College of Rheumatology Ad Hoc Committee on Glucocorticoid- induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum 2001; 44: 1496-1503.
43. Iuliano-Burns S, Saxon L, Naughton G, Gibbons K, Bass SL. Regional specificity of exercise and calcium during skeletal growth in girls: a randomized controlled trial. J Bone Miner Res 2003; 18: 156-162.
44. Matkovic V, Goel PK, Badenhop-Stevens NE et al. Calcium supplementation and bone mineral density in females from childhood to young adulthood: a randomized controlled trial. Am J Clin Nutr 2005; 81: 175-188.
45. Molgaard C, Thomsen BL, Michaelsen KF. The influence of calcium intake and physical activity on bone mineral content and bone size in healthy children and adolescents. Osteoporos Int 2001; 12: 887-894.
46. Zamora SA, Rizzoli R, Belli DC, Slosman DO, Bonjour JP. Vitamin D supplementation during infancy is associated with higher bone mineral mass in prepubertal girls. J Clin Endocrinol Metab 1999; 84: 4541-4544.
47. Amorim Cruz JA. Nutrition and osteoporosis: facts and uncertainties about calcium and vitamin D recommendations. Forum Nutr 2003; 56: 178-181.
48. Winzenberg T, Shaw K, Fryer J, Jones G. Effects of calcium supplementation on bone density in healthy children: meta-analysis of randomised controlled trials. Br Med J 2006; 333: 775.
49. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-1541.
50. Liberman UA, Weiss SR, Broil J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437-1443.
51. Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 1998; 87: 64-68.
52. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947-952.
53. Bianchi ML, Cimaz R, Bardare M, Zulian F, Lepore L, Boncompagni A et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 2000; 43: 1960-1966.
54. Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford) 2005; 44: 813-818.
55. Unal E, Abaci A, Bober E, Buyukgebiz A. Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis. J Pediatr Endocrinol Metab 2006; 19: 523-528.
56. Cimaz R, Gattorno M, Sormani MP et al. Changes in markers of bone turnover and inflammatory variables during alendronate therapy in pediatric patients with rheumatic diseases. J Rheumatol 2002; 29: 1786-1792.
57. Anolik JH, Aringer M. New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract Res Clin Rheumatol 2005; 19: 859-878.
58. Ginzler EM, Dvorkina O. Newer therapeutic approaches for systemic lupus erythematosus. Rheum Dis Clin North Am 2005; 31: 315-328.
59. Schattner A, Naparstek Y. The future of the treatment of systemic lupus erythematosus. Clin Exp Rheumatol 2005; 23: 254-260.
60. Vis M, Havaardsholm EA, Haugeberg G et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1495-1499.
61. Simonini G, Giani T, Stagi S, de Martino M, Falcini F. Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis. Rheumatology (Oxford) 2005; 44: 777-780.